PHAR
Sign in
Pharming Group NV
Save
459.94M
Market cap
–
Current P/E
169.49x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Pharming Group N. V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
Similar securities
Based on sector and market capitalization
Report issue